Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol

Abstract

Objective:

To review the current pharmacology, pharmacokinetics/pharmacodynamics, safety, and efficacy of inclisiran in lowering lipid levels.

Data Sources:

A PubMed (from December 1, 2014 to April 15, 2022) and ClinicalTrials.gov search was conducted using ALN-PCSsc, ALN-60212, PCSK9si KJX-839, and inclisiran. Additional articles were identified by hand from references.

Study Selection and Data Extraction:

We included English-language articles evaluating inclisiran pharmacology, efficacy, or safety in humans for lowering low-density lipoprotein cholesterol (LDL-C).

Data Synthesis:

Inclisiran is a novel small interfering RNA-based therapy administered as a twice-yearly subcutaneous injection. By binding to the messenger RNA (mRNA) precursor of proprotein convertase subtilisin/kexin type 9 (PCSK9), inclisiran inhibits expression of the PCSK9 gene, resulting in increased recycling and expression of LDL receptors and decreased levels of LDL-C. Like PCSK9 inhibitors, inclisiran was associated with a comparable extent of LDL-C reduction in several phase II/III trials. Compared with placebo, inclisiran was found to have similar adverse events except for injection-site reaction.

Relevance to Patient Care and Clinical Practice:

Currently, inclisiran lacks data on clinical outcome improvement or long-term safety. However, it may play a role in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent if optimal LDL-C cannot be achieved by statins and PCSK9 inhibitors cannot be tolerated. The drug may be used for heterozygous familial hypercholesterolemia.

Conclusion:

Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.

Keywords

inclisiran siRNA therapy cholesterol

Get full access to this article

View all access options for this article.

References

Grundy

Stone

Bailey

, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625.

Wong

Young

Zhao

, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011.

Onorato

Sturm

AC.

Heterozygous familial hypercholesterolemia. Circulation. 2016;133(14):e587-e589. doi:10.1161/CIRCULATIONAHA.115.020701.

Familial Hypercholesterolemia—NORD (National Organization for Rare Disorders). Accessed April 17, 2022. https://rarediseases.org/rare-diseases/familial-hypercholesterolemia/.

United States Food and Drug Administration. FDA approves add-on therapy to lower cholesterol among certain high-risk adults. United States Food and Drug Administration. Published 2021. Accessed February 14, 2022. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults.

Urban

Pöss

Böhm

Laufs

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401-1408. doi:10.1016/j.jacc.2013.07.056.

Springer

Dowdy

SF.

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109-118. doi:10.1089/nat.2018.0736.

LEQVIO® (inclisiran) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021.

Sinning

Landmesser

Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 (inclisiran). Curr Cardiol Rep. 2020;22(12):1-7. doi:10.1007/S11886-020-01427-6/TABLES/1.

10.

Zhang

. RNA-induced silencing complex (RISC). In: Encyclopedia of Systems Biology. New York: Springer; 2013:1876. doi:10.1007/978-1-4419-9863-7_329.

11.

Sehgal

Vaishnaw

Fitzgerald

Liver as a target for oligonucleotide therapeutics. J Hepatol. 2013;59(6):1354-1359. doi:10.1016/j.jhep.2013.05.045.

12.

Karaki

Paris

Rocchi

. Antisense oligonucleotides, a novel developing targeting therapy. In: Antisense Therapy. IntechOpen; 2019. doi:10.5772/INTECHOPEN.82105.

13.

Mäkinen

Ruotsalainen

Ylä-Herttuala

Nucleic acid–based therapies for atherosclerosis. Curr Atheroscler Rep. 2020;22(2):1-8. doi:10.1007/S11883-020-0826-2/TABLES/1.

14.

Wright

Collins

Stoekenbroek

, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77-89. doi:10.1016/j.mayocp.2019.08.021.

15.

National Institutes of Health (NIH). Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C (ORION-8), https://clinicaltrials.gov/ct2/show/NCT03814187 (20.10.2021). Published 2021. Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03814187?term=ORION-8&draw=2&rank=1.

16.

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5). Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03851705.

17.

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia. Published 2021. Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT04659863.

18.

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7). Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03159416.

19.

A Randomized Study to Evaluate the Effect of an “Inclisiran First” Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-IN). Published 2021. Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT04929249.

20.

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome. Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT04873934.

21.

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). US National Library of medicine. Published 2021. Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03705234.

22.

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P). Accessed February 14, 2022. https://clinicaltrials.gov/ct2/show/NCT05030428.

23.

Ray

Landmesser

Leiter

, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/nejmoa1615758.

24.

Hovingh

Lepor

Kallend

Stoekenbroek

Wijngaard

PLJ

Raal

FJ.

Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study. Circulation. 2020;141(22):1829-1831. doi:10.1161/CIRCULATIONAHA.119.044431.

25.

Kastelein

JJP

. ORION—3—Long-term inclisiran in subjects with high CV risk and elevated LDL-C. In: National Lipid Association Scientific Sessions; 2019. Accessed February 14, 2022. https://www.lipid.org/sites/default/files/files/ORION-3NLAMay162019.pdf.

26.

Raal

Kallend

Ray

, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. doi:10.1056/nejmoa1913805.

27.

Ray

Wright

Kallend

, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/nejmoa1912387.

28.

Wright

Ray

Raal

, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058.

29.

Landmesser

Haghikia

Leiter

, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284-291. doi:10.1093/cvr/cvaa077.

30.

Sabatine

Giugliano

Keech

, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/nejmoa1615664.

31.

Schwartz

Steg

Szarek

, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/nejmoa1801174.

32.

Asbeutah

AAA

Asbeutah

Abu-Assi

. A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran. Am J Cardiol. 2020;128:218-219. doi:10.1016/J.AMJCARD.2020.05.024.

33.

Khan

Naz

Qamar Masood

Shah

Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69-73. doi:10.1016/J.AMJCARD.2020.08.018.

34.

Novartis Investor Presentation. Leqvio® FDA approval. NOVARTIS. Published December 23, 2021. Accessed February 14, 2022. https://www.novartis.com/sites/novartis_com/files/novartis-leqvio-approval-presentation.pdf.

35.

Lin

Kazi

Jih

Agboola

Chapman

Pearson

SD.

Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value; final evidence report. Institute for Clinical and Economic Review, March 2, 2021.